Hypera S.A. (BVMF:HYPE3)

Market Cap	16.05B
Revenue (ttm)	6.70B
Net Income (ttm)	808.80M
Shares Out	631.80M
EPS (ttm)	1.27
PE Ratio	19.94
Forward PE	9.75
Dividend	1.17 (4.64%)
Ex-Dividend Date	Mar 28, 2025

Volume	920,800
Average Volume	2,968,205
Open	25.39
Previous Close	25.40
Day's Range	24.91 - 25.51
52-Week Range	16.62 - 32.38
Beta	0.36
RSI	65.17
Earnings Date	Aug 7, 2025

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 10,481
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: HYPE3

Financial Performance

In 2024, Hypera's revenue was 7.44 billion, a decrease of -5.97% compared to the previous year's 7.91 billion. Earnings were 1.34 billion, a decrease of -18.63%.